TCR2 Therapeutics
consistent tumor regression in patients with | TCR2 Therapeutics
Company
Deck Type
Sector
Industry
Deck date
September 2022
Slide
18 of 34
Similar slides by TCR2 Therapeutics
See diffirences between slides (animation)
Results
September 2022
clinical activity at or below | TCR2 Therapeutics
Results
September 2022
survival in ovarian cancer after infusion | TCR2 Therapeutics
Results
September 2022
phase data support a path forward as leader | TCR2 Therapeutics
Results
September 2022
promising signal in platinum refractory ovarian cancer months months | TCR2 Therapeutics
Related slides by other companies
BioAtla
Investor Presentation
January 2024
phase cab demographics tumor types | BioAtla
Recursion Pharmaceuticals
Investor Day
January 2023
clinical well understood clinical safety with a drug like profile further confidence prior studies suggestive of potential therapeutic benefit | Recursion Pharmaceuticals
Nuvalent
Investor Presentation
February 2024
time on treatment sustained duration with follow up ongoing phase i a a prior alk including prior alk no and subsequently confirmed pending confirmation all patients tumor response remain without disease progression response evaluable patients continue median range of months median range to response weeks months data as of august for response evaluable patients progressive disease partial response once daily tyrosine kinase inhibitor source lin | Nuvalent
Genelux
Investor Presentation
October 2023
demonstrated deep and durable tumor shrinkage | Genelux
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io